Travere Therapeutics (TVTX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Twist Bioscience (TWST) has outperformed Travere Therapeutics (TVTX) over the past year, gaining 363.7% versus a gain of 98.6%. Over five years, TVTX leads with a +112.4% price change compared with +34.8% for TWST. Twist Bioscience is the larger company by market cap ($10.08 billion vs $4.91 billion), about 2.1 times the size, while Travere Therapeutics is growing revenue faster (+110.5% vs +20.3%).
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -20.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TVTX | TWST |
|---|---|---|
| Share price | $52.04 | $152.05 |
| Market cap | $4.91B | $10.08B |
| 1-day change | -2.62% | -2.31% |
| YTD return | +36.19% | +379.35% |
| 1-year return | +98.63% | +363.71% |
| 5-year return | +112.41% | +34.80% |
| Forward P/E | 9.23 | — |
| EPS (TTM) | $-0.74 | $-2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $490.73M | $376.57M |
| Revenue growth (YoY) | +110.45% | +20.32% |
| Net income (latest FY) | $-25.55M | $-77.67M |
| Gross margin | 97.89% | 50.72% |
| Operating margin | -12.80% | -36.18% |
| Net margin | -5.21% | -20.63% |
| 52-week high | $68.73 | $219.71 |
| 52-week low | $22.59 | $23.30 |
| Distance from 52-week high | -24.28% | -30.80% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +44.52% | -1.13% |
| Average volume | 1.59M | 2.04M |
| Shares outstanding | 94.26M | 66.30M |
| Employees | 497 | 979 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Twist Bioscience is about 2.1 times larger than Travere Therapeutics by market value ($10.08B vs $4.91B).
- TWST has outperformed TVTX by 265.1 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -20.6 cents for Twist Bioscience.
- Travere Therapeutics grew revenue faster in its latest fiscal year (+110.45% vs +20.32%).
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Healthcare · Biotechnology · 497 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Healthcare · Biotechnology · 979 employees
TVTX vs TWST FAQ
Which is bigger, Travere Therapeutics or Twist Bioscience?
Twist Bioscience (TWST) is larger, with a market capitalization of $10.08B compared with $4.91B for Travere Therapeutics (TVTX).
Which stock has performed better over the past year, TVTX or TWST?
TWST returned +363.71% over the past 12 months, compared with +98.63% for TVTX (price return, excluding dividends). Past performance does not predict future results.
Are Travere Therapeutics and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.